BeiGene, Ltd. (688235.SS)
CNY 238.8
(-2.96%)
CNY 238.8
(-2.96%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 930.18 Million USD | 4.38% |
| 2022 | 891.12 Million USD | 28.29% |
| 2021 | 694.64 Million USD | 23.61% |
| 2020 | 561.96 Million USD | 102.62% |
| 2019 | 277.34 Million USD | 39.79% |
| 2018 | 198.4 Million USD | 20.45% |
| 2017 | 164.71 Million USD | 852.99% |
| 2016 | 17.28 Million USD | -16.85% |
| 2015 | 20.78 Million USD | 50.21% |
| 2014 | 13.83 Million USD | -49.43% |
| 2013 | 27.36 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.06 Billion USD | 14.29% |
| 2024 Q2 | 1.08 Billion USD | 2.53% |
| 2023 FY | 930.18 Million USD | 4.38% |
| 2023 Q3 | 579.77 Million USD | -14.46% |
| 2023 Q4 | 930.18 Million USD | 60.44% |
| 2023 Q1 | 545.19 Million USD | -38.82% |
| 2023 Q2 | 677.8 Million USD | 24.32% |
| 2022 Q4 | 891.12 Million USD | 25.41% |
| 2022 Q3 | 710.57 Million USD | 12.32% |
| 2022 Q2 | 632.64 Million USD | -5.84% |
| 2022 FY | 891.12 Million USD | 28.29% |
| 2022 Q1 | 671.87 Million USD | -3.28% |
| 2021 FY | 694.64 Million USD | 23.61% |
| 2021 Q2 | 680.38 Million USD | 6.54% |
| 2021 Q1 | 638.62 Million USD | 13.64% |
| 2021 Q3 | 699.53 Million USD | 2.82% |
| 2021 Q4 | 694.64 Million USD | -0.7% |
| 2020 Q3 | 243.73 Million USD | -32.63% |
| 2020 FY | 561.96 Million USD | 102.62% |
| 2020 Q4 | 561.96 Million USD | 130.57% |
| 2020 Q2 | 361.76 Million USD | 21.38% |
| 2020 Q1 | 298.05 Million USD | 7.47% |
| 2019 Q4 | 277.34 Million USD | -2.76% |
| 2019 Q3 | 285.2 Million USD | 3.57% |
| 2019 Q1 | 270.59 Million USD | 36.39% |
| 2019 Q2 | 275.37 Million USD | 1.77% |
| 2019 FY | 277.34 Million USD | 39.79% |
| 2018 Q3 | 195.96 Million USD | -6.57% |
| 2018 Q2 | 209.75 Million USD | 20.77% |
| 2018 Q1 | 173.68 Million USD | 5.44% |
| 2018 FY | 198.4 Million USD | 20.45% |
| 2018 Q4 | 198.4 Million USD | 1.24% |
| 2017 Q2 | 152.72 Million USD | 667.32% |
| 2017 Q1 | 19.9 Million USD | 15.16% |
| 2017 FY | 164.71 Million USD | 852.99% |
| 2017 Q4 | 164.71 Million USD | 4.02% |
| 2017 Q3 | 158.34 Million USD | 3.68% |
| 2016 Q1 | 6.21 Million USD | -70.1% |
| 2016 Q2 | 10.55 Million USD | 69.83% |
| 2016 FY | 17.28 Million USD | -16.85% |
| 2016 Q4 | 17.28 Million USD | -4.14% |
| 2016 Q3 | 18.03 Million USD | 70.85% |
| 2015 Q3 | 20.62 Million USD | 46.84% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 20.78 Million USD | 0.76% |
| 2015 Q2 | 14.04 Million USD | 0.0% |
| 2015 FY | 20.78 Million USD | 50.21% |
| 2014 FY | 13.83 Million USD | -49.43% |
| 2014 Q4 | 13.83 Million USD | 0.0% |
| 2013 FY | 27.36 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Shanghai No.1 Pharmacy Co., Ltd. | 326.9 Million CNY | -184.539% |
| Jointown Pharmaceutical Group Co., Ltd | 38.76 Billion CNY | 97.601% |
| LBX Pharmacy Chain Joint Stock Company | 9.86 Billion CNY | 90.568% |
| Yifeng Pharmacy Chain Co., Ltd. | 10.05 Billion CNY | 90.749% |
| Yunnan Jianzhijia Health-Chain Co., Ltd. | 3.69 Billion CNY | 74.832% |